

- Canagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2) approved for the treatment of adults with type 2 diabetes mellitus (T2DM).
- Efficacy, safety, and tolerability of canagliflozin 100 and 300 mg compared with placebo added to sulfonylurea monotherapy are reported from a prespecified, 18-week substudy of patients with T2DM enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS), an ongoing cardiovascular outcomes study.
- Canagliflozin 100 or 300 mg added to sulfonylurea monotherapy lowered glycated hemoglobin compared with placebo; canagliflozin 300 mg provided weight loss versus placebo.
- Canagliflozin 100 and 300 mg were generally well tolerated, with increased incidence of adverse events related to the mechanism of SGLT2 inhibition.
- This study supports the efficacy and safety of canagliflozin for use as add-on to sulfonylurea monotherapy in patients with T2DM and cardiovascular risk.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Janssen Research & Development, LLC. Medical writing assistance for this study was provided by MedErgy (A DeToma). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).